Quality And Compliance In Times Of Crisis
Source: Dassault Systèmes
Already in 2020, the FDA has issued in excess of 50 warning letters to organizations that are COVID-19 related. How will this impact the approach to validated systems in the future and what bearing will it have on the risk-based approach that the regulatory authorities have been taking to Quality Management Systems?
During this webinar, see how the quality management systems of a life sciences company operate, how a collaborative secure deployment looks like and how it can be adapted to maintaining data integrity in order to deliver drugs to market quicker with the following key benefits:
- 60% increase in right-first-time submissions
- 80% reduction in approval times
- 85% improvement in regulatory compliance
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.
Subscribe to Drug Discovery Online
X
Subscribe to Drug Discovery Online
Dassault Systèmes
This website uses cookies to ensure you get the best experience on our website. Learn more